Why Zoetis is back on investors’ radar
Fresh peer reviewed data on Simparica Trio has put Zoetis (ZTS) in focus, showing stronger protection against a resistant heartworm strain than rival NexGard Plus and sharpening attention on the stock’s animal health franchise.
Recent trading reflects that tension between pressure and potential. Zoetis shares are up 2.14% on a 1-day share price return and 5.76% over 7 days, yet the stock is still down sharply with a 1-year total shareholder return that has declined 48.06% and a 5-year total shareholder return that has fallen 61.42%. As a result, the latest Simparica Trio data and recent dividend declaration appear to be feeding into a modest rebound in sentiment rather than a full reset.
Scan how Zoetis compares with other animal health and pharma players that currently screen as 27 high quality undervalued stocks.
After a sharp reset and a short bounce, Zoetis now sits in that awkward middle ground where value hunters eye the drawdown while others wait for an even cheaper entry. So what are you really paying for here?
Most Popular Narrative: 21% Undervalued
Zoetis last closed at $73.08, while the most followed narrative pegs fair value at $92.92. The gap between price and story is already clear before you even look at the heartworm headlines.
The main reason for the recent collapse in the share price was because they reported that the US Companion Animal segment saw an 11% year-over-year decline in segment revenues. As that is where they are supposed to be focusing most, given the higher margins and higher defensibility or moat of profits of the Pet segment, it is not surprising that it resulted in a 30% drop in the share price after Q1 earnings.
See why 30 investors see Zoetis as 21% undervalued.
Result: Fair Value of $92.92 (UNDERVALUED)
Still, the Zoetis story can break if US companion animal weakness persists, or if generic competitors chip away faster at key, high concentration products.
Find out about the key risks to this Zoetis narrative.
Next Steps
With sentiment this mixed around Zoetis, it helps to move fast, pull up the core facts and stress test the story yourself. To see both the potential upside and the issues investors are worried about, start with the 4 key rewards and 1 important warning sign.
Looking for more Zoetis investment ideas?
Do not stop at Zoetis alone. Use the Simply Wall St screener to line up fresh contenders, compare fundamentals quickly, and spot opportunities before everyone else does.
- Target income first by scanning dependable high-yield opportunities through the 8 dividend fortresses.
- Hunt for quality at a discount by reviewing the 27 high quality undervalued stocks that combine solid fundamentals with attractive pricing.
- Protect your downside by focusing on stability using the 31 resilient stocks with low risk scores that score well on resilience and financial strength.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com